Trending Investment Opportunities
Advertisement
- At the start of March, BridgeBio Pharma Inc BBIO won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A.
- In the middle of March, it announced positive proof-of-concept data for encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1).
- Today, the company is wrapping up the busy month with global collaboration and licensing agreement with Helsinn Group to develop and commercialize infigratinib.
- The agreement covers oncology and all other indications except for skeletal dysplasias (including achondroplasia).
- Infigratinib is an orally administered ATP-competitive tyrosine kinase inhibitor designed to inhibit FGFR.
- Under the terms of the Agreement, BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia.
- Subject to FDA approval, BridgeBio Pharma's affiliate QED Therapeutics and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. on a 50:50 basis.
- Under the Agreement, BridgeBio will be eligible to receive more than $2 billion in upfront, regulatory and commercial milestones, as well as tiered royalties on adjusted net sales from Helsinn Group.
- Helsinn will have exclusive commercialization rights and lead commercialization for infigratinib in non-skeletal dysplasia indications outside of the U.S., excluding China, Hong Kong, and Macau, covered under LianBio collaboration.
- Price Action: BBIO shares are up 2.54% at $60.62 in market trading hours on the last check Wednesday.
Loading...
Loading...
BBIOBridgeBio Pharma Inc
$46.51-0.49%
Edge Rankings
Momentum
92.63
Growth
N/A
Quality
N/A
Value
6.26
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
